Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia.

We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was performed after an interval of one week. All patients achieved clinically significant responses to ATO. The overall complete response rate and overall response rate at 17 weeks were 60% (3/5) and 100%(5/5), respectively. So treatment with ATO may be a feasible approach in patients with refractory SAA.

Citation

Ning Li, Yongping Song, Jian Zhou, Baijun Fang. Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia. Journal of hematology & oncology. 2012 Oct 09;5:61

Mesh Tags

Substances

PMID: 23044093

search → result